AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effectiveness and Implementation Evaluation of NeoMayor for Improving Cardiovascular Health in Chilean Older Adults

RecruitingNAAges 55 Years - 75 YearsAllUniversity of Chile
💬

In plain words

What the trial is, and whether it could suit you

This study aims to evaluate the effectiveness and implementation of NeoMayor, a mobile health (mHealth) intervention designed to improve cardiovascular health among older adults at elevated cardiovascular risk in Chile. NeoMayor is a smartphone-based application that provides personalized guidance on physical activity, diet, sleep, and mental well-being through a multidomain lifestyle approach. This multicenter randomized controlled trial will enroll community-dwelling older adults aged 55 to 75 years recruited from primary healthcare centers in urban and rural settings. Participants will be randomized in a 2:1 ratio to either the NeoMayor intervention or a control group receiving standard health information and usual care. The intervention duration will be four months. The primary objective is to determine whether NeoMayor improves cardiovascularhealth, measured with the Life's Essent

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion criteria * Age between 55 and 75 years * Able to read and understand written instructions * Ownership of a smartphone and ability to use it independently * Physically inactive, defined as performing less than 30 minutes of daily physical activity or less than 2,5 h a week. * Intermediate or high cardiovascular risk, defined as the presence of at least three of the following: Hypertension (history diagnosed by specialist or general practitioner or ≥ 140 mmHg systolic or ≥90 mm Hg diastolic blood pressure at baseline or current antihypertensive treatment);Diabetes Mellitus (history diagnosed by specialist or general practitioner or fasting blood glucose ≥126 mg/dL or current pharmacologic treatment);Obesity (BMI ≥30 kg/m²); Dyslipidaemia (history diagnosed by specialist or general practitioner or lipid-lowering drugs or baseline total cholesterol ≥ 200 mg/dL or LDL cholesterol ≥100 mg/dL). Exclusion Criteria * Dementia defined as a score in the MEFO \< 9 * Significant limitations for independent mobility, including use of assistive devices, frailty, gait instability, or lower-limb painful conditions limiting physical activity * Uncorrected hearing or visual impairment preventing adequate use of a smartphone * Chronic neurological, psychiatric, or psychological disorders without regular treatment or follow-up. * Present severe alcohol or illicit drug use. * Severe or terminal illness
💊

What it tests

  • NeoMayor App
  • Wearable Device Support
  • Human Health Coach Support
📍

Where

2 sites
Hospital clinico Universidad de Chile. Carlos Lorca Tobar 999
Santiago, Chile
Hospital de Til til Daniel Moya #100
Tiltil, Chile
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy